iCAD boosts NMSC offering with DermEbx and Radion’s acquisition

iCAD has signed definitive agreement to acquire DermEbx and Radion for approximately $12.6m.

The transaction is expected to add the necessary components designed to enable dermatologists and radiation oncologists to develop, launch and expand electronic brachytherapy programmes for non-melanoma skin cancer (NMSC) treatment to the company’s Xoft Electronic Brachytherapy (eBx(R) ) System(R) product line.

Specifically, the acquisition would expand the Xoft suite to include physics support, billing support, assistance with radiation oncology provider selection, as well as the Radion Hub cloud-based oncology collaboration software solution.

iCAD president and CEO Ken Ferry said the adoption of eBx technology for the treatment of non-melanoma skin cancer resulted in a record number of systems placed in 2013.

The company is impressed with total solution and workflow benefits of DermEbx and Radion, and expects to accelerate their market adoption by streamlining them into one seamless offering, Ferry added.

"The strategic rationale for these acquisitions is clear and its potential to iCAD and the treatment of non-melanoma skin cancer is significant as we expand our comprehensive solution offering to radiation oncology and dermatology practices."

DermEbx and Radion president Kamal Gogineni said, "This transaction builds upon our established collaborative foundation to provide state-of-the-art technology supported by patient-centric solutions and services through a proprietary oncology solution."

A US Food and Drug Administration-cleared isotope-free radiation treatment approved for early-stage breast cancer, gynecological cancers and NMSC, Xoft System uses a proprietary miniaturised X-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs.

Radion Hub is a web-based platform designed to enable centres to improve patient safety, conduct treatment planning, enhance and monitor workflow, as well as improve communication between clinical specialists.